Physician profile
Thomas Andrew Burrow
NPI 1699983155
$108,375.45
in general payments reported to CMS, 2019-2025
15 companies · $16K in 2025
The $16K reported for 2025 was more than what 89% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $9,790 · 2021: $11K · 2022: $2,400 · 2023: $14K · 2024: $43K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Travel and Lodging: $2,701 · Honoraria: $1,575 · Food and Beverage: $937 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $66,669.60 |
| Travel and Lodging | $2,701.46 |
| Honoraria | $1,575.00 |
| Food and Beverage | $936.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $39,650.00 | 2023-2025 | |
| Genzyme Corporation | $38,214.63 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,800.00 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $8,767.00 | 2019-2023 | |
| Shire North American Group INC | $6,430.66 | 2019 | |
| Sanofi US Services INC. | $2,000.00 | 2020 | |
| Bioverativ Therapeutics INC. | $1,890.00 | 2020 | |
| Intrabio INC | $1,575.00 | 2025 | Aqneursa |
| Alexion Pharmaceuticals, INC. | $1,025.00 | 2025 | Strensiq |
| Eton Pharmaceuticals, INC. | $23.16 | 2025 | Carglumic Acid, Galzin, Betaine Anhydrous |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.